Westbourne Investments Inc. Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Westbourne Investments Inc. acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 500 shares of the biopharmaceutical company's stock, valued at approximately $356,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Virtu Financial LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $6,364,000. Morse Asset Management Inc increased its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the third quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company's stock valued at $5,053,000 after purchasing an additional 43 shares during the period. Anchor Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 212.0% during the third quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company's stock valued at $902,000 after purchasing an additional 583 shares in the last quarter. Sculati Wealth Management LLC lifted its holdings in Regeneron Pharmaceuticals by 1.9% in the third quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company's stock worth $1,970,000 after purchasing an additional 38 shares during the period. Finally, Pine Valley Investments Ltd Liability Co grew its position in Regeneron Pharmaceuticals by 19.0% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company's stock valued at $5,575,000 after buying an additional 848 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on REGN shares. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Bank of America dropped their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a report on Thursday, April 17th. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday. Bernstein Bank lowered their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $892.60.

Regeneron Pharmaceuticals Stock Up 2.6 %

Shares of REGN stock traded up $15.61 on Friday, reaching $605.61. 1,606,415 shares of the company's stock traded hands, compared to its average volume of 745,022. The company has a market capitalization of $66.21 billion, a P/E ratio of 15.82, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 12-month low of $525.99 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The business's 50 day moving average price is $626.49 and its two-hundred day moving average price is $709.39.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's revenue was down 3.7% compared to the same quarter last year. During the same period last year, the company posted $9.55 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.